Next Article in Journal
Trends and Changes in Treating Proximal Humeral Fractures in Italy: Is Arthroplasty an Increasingly Preferred Option? A Nation-Wide, Population-Based Study over a Period of 22 Years
Previous Article in Journal
Biofilm Formation, Antibiotic Resistance, and Infection (BARI): The Triangle of Death
Previous Article in Special Issue
Predictivity of the Prognostic Nutritional Index and Systemic Inflammation Index for All-Cause In-Hospital Mortality in Geriatric and Adult COVID-19 Inpatients
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JCM
Volume 13
Issue 19
10.3390/jcm13195777
jcm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

The Model for End-Stage Liver Disease (MELD) Score Predicting Mortality Due to SARS-CoV-2 in Mexican Patients

by
José Manuel Reyes-Ruiz
1,*,
Ana Citlali Avelino-Santiago
1,
Gustavo Martínez-Mier
1,
Claudia Vanessa López-López
2,3,
Luis Adrián De Jesús-González
4,
Moises León-Juárez
5,
Juan Fidel Osuna-Ramos
6,
Carlos Noe Farfan-Morales
7,8,
Selvin Noé Palacios-Rápalo
9,
Víctor Bernal-Dolores
1 and
Rosa María Del Ángel
8
1
Unidad Médica de Alta Especialidad, Hospital de Especialidades No. 14, Centro Médico Nacional “Adolfo Ruiz Cortines”, Instituto Mexicano del Seguro Social (IMSS), Veracruz 91897, Mexico
2
Facultad de Medicina, Complejo Regional Sur Tehuacán, Benemérita Universidad Autónoma de Puebla (BUAP), Puebla 7585, Mexico
3
Programa Interinstitucional para el Fortalecimiento de la Investigación y el Posgrado del Pacífico (Programa Delfín), Tepic 63000, Mexico
4
Unidad de Investigación Biomédica de Zacatecas, Instituto Mexicano del Seguro Social, Zacatecas 98000, Mexico
5
Laboratorio de Virología Perinatal y Diseño Molecular de Antígenos y Biomarcadores, Departamento de Inmunobioquimica, Instituto Nacional de Perinatología, Mexico City 11000, Mexico
6
Facultad de Medicina, Universidad Autónoma de Sinaloa, Culiacán 80019, Mexico
7
Departamento de Ciencias Naturales, Universidad Autónoma Metropolitana (UAM), Unidad Cuajimalpa, Mexico City 05348, Mexico
8
Department of Infectomics and Molecular Pathogenesis, Center for Research and Advanced Studies (CINVESTAV-IPN), Mexico City 07360, Mexico
9
Institut Pasteur, Unité de Virologie Structurale, 75015 Paris, France
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2024, 13(19), 5777; https://doi.org/10.3390/jcm13195777
Submission received: 20 August 2024 / Revised: 20 September 2024 / Accepted: 25 September 2024 / Published: 27 September 2024
(This article belongs to the Special Issue Laboratory Biomarkers in the Clinical Management of COVID-19 and Post-COVID-19 Conditions)
Browse Figures
Versions Notes

Abstract

:
Background/Objectives: Coronavirus Disease 2019 (COVID-19) can cause liver injury and a deterioration of hepatic function. The Model for End-Stage Liver Disease (MELD) score is a good predictor for poor prognosis of hospitalized COVID-19 patients in the United States, Egypt and Turkey. Nevertheless, the best cut-off value for the MELD score to predict mortality in the Mexican population has yet to be established. Methods: A total of 234 patients with COVID-19 were studied in a tertiary-level hospital. Patients were stratified into survivors (n = 139) and non-survivors (n = 95). Receiver operating characteristic curves, Cox proportional hazard models, Kaplan–Meier method, and Bonferroni corrections were performed to identify the predictors of COVID-19 mortality. Results: MELD score had an area under the curve of 0.62 (95% CI: 0.56–0.68; p = 0.0009), sensitivity = 53.68%, and specificity = 73.38%. Univariate Cox proportional hazard regression analysis suggested that the leukocytes > 10.6, neutrophils > 8.42, neutrophil-to-lymphocyte ratio (NLR) > 8.69, systemic immune-inflammation index (SII) > 1809.21, MELD score > 9, and leukocyte glucose index (LGI) > 2.41 were predictors for mortality. However, the multivariate Cox proportional hazard model revealed that only the MELD score >9 (Hazard Ratio [HR] = 1.83; 95% confidence interval [CI]: 1.2–2.8; Pcorrected = 0.03) was an independent predictor for mortality of COVID-19. Conclusions: Although the MELD score is used for liver transplantation, we suggest that a MELD score >9 could be an accurate predictor for COVID-19 mortality at admission to ICU requiring mechanical ventilation.

1. Introduction

Since 2020, the coronavirus disease 2019 (COVID-19) pandemic has been one of the main risks to public health worldwide as an outcome of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, belonging to the Coronaviridae [1]. COVID-19 causes a syndrome with non-specific characteristics that includes fever, dry cough, dyspnea, and fatigue, but it can also harm the organs, including the liver [2]. Alterations in liver function tests, mainly manifested by a significant elevation of hepatic enzymes and bilirubin in hospitalized patients with COVID-19 are evidence of the existing liver damage associated with SARS-CoV-2 infection [3,4]. COVID-19-associated liver injury has been defined as any hepatic damage that occurs during the patient’s illness and treatment with COVID-19, with or without a history of liver disease, causing an unfavorable prognosis and higher risk of mortality [4,5]. The damage caused to the liver during SARS-CoV-2 infection could be related to the direct cytopathic effect on hepatocytes and underlying organs or the hyperinflammation and cytokine storm [6].
The model for end-stage liver disease (MELD score), which is calculated with three standard laboratory variables (international normalized ratio (INR), serum creatinine, and total bilirubin), was created as a predictive value for mortality in patients with trans-jugular intrahepatic portosystemic shunts by complications of portal hypertension [7]. MELD score also has application in chronic liver disease and liver transplant allocation [7]. Studies that were performed in the African, Asian and North American populations have shown the usefulness of the MELD score for predicting the risk of hospital mortality in patients with COVID-19 [8,9,10]. However, more information is needed on the prediction capacity of this biomarker in other populations. Therefore, this paper aimed to assess the predictive value of the MELD score for mortality of patients with COVID-19 in the Mexican population without a history of chronic liver disease. For this study, the MELD score was compared with the biomarkers for SARS-CoV-2 infection to extend the knowledge available on the potential of the predictors of mortality at admission to ICU requiring mechanical ventilation.

2. Materials and Methods

2.1. Study Design and Participants

This retrospective and cross-sectional study was conducted following the Declaration of Helsinki at a tertiary care hospital from the Mexican Social Security Institute (IMSS). This study was approved in 2024 by the local research ethical Committee (R-2024-3001-113). Patients diagnosed with COVID-19 by a positive nucleic acid test for SARS-CoV-2 and admitted from June to December 2021 to the intensive care unit (ICU) with acute respiratory distress and invasive mechanical ventilation were screened for inclusion in the study. Subjects with the following characteristics were excluded from the study: aged less than 18 years, acquired immune deficiency syndrome, liver cirrhosis, liver cancer, malignant tumor, non-alcoholic and alcoholic fatty liver diseases, and pregnancy. All the patients were admitted for COVID-19 to the ICU, and the patients with other causes of mortality and additional SARS-CoV-2 infection were excluded from the study.

2.2. Data Collection

All laboratory (leukocytes, neutrophils, lymphocytes, platelets, glucose, urea, creatinine, total bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT)), and demographic (sex, age, height, weight, body mass index (BMI), diabetes, and hypertension) data were obtained from the electronic health records. Blood samples for hematologic and biochemical parameters assessment were collected within 24 h after admission and measurements within 1 h of sample collection. The routine blood tests were analyzed using the Sysmex XN-1000 Automated Hematology Analyzer (Sysmex, Kobe, Japan) and 3-level quality controls (Hematology Control XN Check). VITROS 4600 Chemistry System (Ortho Clinical Diagnostics, Raritan, NJ, USA) was used to assess the biochemical parameters.

2.3. Outcome and Exposure Variable

The in-hospital mortality of the COVID-19 hospitalized patients was evaluated as an outcome variable. The mortality of the patients after discharge from the hospital was not considered. MELD score was the exposure variable and was calculated using bilirubin, creatinine, and international normalized ratio (INR) with the formula 9.57 × loge (creatinine) + 3.78 × loge (total bilirubin) + 11.2 × loge (INR) + 6.43 [7]. The length of hospital stay was considered for the analysis of Cox and Kaplan–Meier.

2.4. Laboratory Biomarkers Reported for COVID-19

The AST-to-lymphocyte ratio index (ALRI) was provided by the formula ALRI = aspartate aminotransferase (U/L)/lymphocyte [11]. APRI was given by AST (U/L)/upper limit of normal value (U/L)/platelet count × 100 [12]. AST-to-neutrophil ratio index (ANRI) was obtained by dividing the AST (U/L) by the neutrophil count [13]. Neutrophil/lymphocyte ratio (NLR) = the total absolute neutrophil counts over total lymphocyte counts [14]. Platelets-to-lymphocyte ratio (PLR) = absolute platelet count/absolute lymphocyte count [15]. SII = platelet count × neutrophil count/lymphocyte count (×109/L) [16]. The leukocyte glucose index (LGI) was defined as the product between blood leukocytes counts and glucose levels divided by 1000 [17]. Lactate dehydrogenase (LDH)/lymphocyte ratio = LDH levels (U/L)/lymphocyte counts (cells/µL) [18]. Blood urea nitrogen/creatinine (BUN/Cr) ratio = BUN/Cr (mg/dL) [19].

2.5. Statistical Analysis

Quantitative variables were expressed as mean ± standard deviation or median (interquartile range). Categorical variables were described as numbers (%). The distribution of quantitative variables was evaluated using the Shapiro–Wilk test, Q-Q plots, and histograms. Mann–Whitney test or Student’s t-test were used to compare continuous variables between the two cohorts. The Chi-square test was used for categorical variables. Spearman correlation coefficient was used to determine the correlations between continuous variables. The accuracy of the hematologic and biochemical parameters in predicting COVID-19 mortality was calculated using the Receiver Operator Characteristic (ROC) curve, obtaining the area under the curve (AUC), specificity, and sensitivity. Youden’s-J index was used to find the best cut-off value. Leukocytes, neutrophils, NLR, SII, MELD score and LGI levels were categorized into two groups by defining the best cut-off obtained of Youden’s-J statistic on the ROC curve. Survival curves were estimated using the Kaplan–Meier method, where the 22-day outcomes of these groups were assessed using the long-rank test. Univariate and multivariate Cox proportional hazards regression analysis were performed to calculate the hazard ratio (HR) with a corresponding 95% confidence interval (CI). The variables showing significant results in the univariate Cox regression analysis were selected to be tested in the multivariate Cox regression analysis. Univariate and multivariate logistic regression analysis was performed to determine the predictive factors for MELD score >9 in patients with COVID-19. The Odds Ratios (OR) with a corresponding 95% CI were calculated. A p-value < 0.05 was defined as statistically significant. p values were adjusted using the Bonferroni corrections (Pcorrected) to compensate for the effect of multiple hypothesis testing. All statistical analyses were performed with MedCalc v.18.2.18, SPSS Statistics v.26, and R v4.03 Statistical Software.

3. Results

3.1. Sample Overview

A total of 234 patients with COVID-19 were included in this study, among which were 139 surviving and 95 non-surviving. The mean age of non-survival was 65.23 ± 13.86, and the survival group was 62.74 ± 12.678 (Pcorrected = 0.190). The median fraction of the surviving patients’ inspired oxygen (FiO2) and oxygen saturation (SpO2) were 41% and 71%, respectively, whereas the patients who did not survive showed a FiO2 and SpO2 of 60% and 58.5%, respectively. The leukocytes, neutrophils, NLR, SII, MELD, and LGI values were significantly older in the non-survivor group than in the survivor group (Pcorrected < 0.05). The other biochemical and hematological parameters had no significant relationship between the groups studied (Pcorrected > 0.05). The data for the patients are summarized in Table 1.

3.2. Assessment of the Hematologic and Biochemical Parameters for Predicting COVID-19 Mortality

ROC analysis in predicting COVID-19 mortality was performed for all variables that remained significant after the multiple hypothesis correction (Pcorrected < 0.05) (Figure 1A). The AUC for leukocytes, neutrophils, NLR, SII, MELD, and LGI were 0.64 (sensitivity = 66.32%; specificity = 64.03%), 0.65 (sensitivity = 69.47%; specificity = 58.99%), 0.64 (sensitivity = 70.53%; specificity = 57.55%), 0.62 (sensitivity= 78.95%; specificity = 45.32%), 0.62 (sensitivity = 53.68%; specificity = 73.38%), and 0.64 (sensitivity = 44.21%; specificity = 78.42%), respectively (Figure 1B).

3.3. Survival Analysis Using Kaplan–Meier Curves

To identify the variables associated with COVID-19 mortality, the leukocytes, neutrophils, NLR, SII, MELD, and LGI were included in the analysis of Kaplan–Meier curves, which were created using the best cut-off points for each variable. COVID-19 patients above the stated leukocytes (>10.6 = 12.72 days vs. ≤10.6 = 17.68 days; p < 0.0001), neutrophils (>8.42 = 13.07 days vs. ≤8.42 = 17.74 days; p < 0.0001), NLR (>8.69 = 13.15 days vs. ≤8.69 = 17.77 days; p < 0.0001), SII (>1809.21 = 13.69 days vs. ≤1809.21 = 18.19 days; p = 0.0001), MELD score (>9 = 12.31 days vs. ≤9 = 17.08 days; p < 0.0001), and LGI (>2.41 = 12.16 days vs. ≤2.41 = 16.67 days; p = 0.0001) best cut-off values had a lower median survival time compared to those with values less than or equal to the best cut-off point (Figure 2A–F). All the parameters showed a significant difference (Log-rank (Mantel-Cox) < 0.0005) in survival between the between the high and low groups according to the best cut-off point at 22 days.

3.4. MELD Score Is a Predictor of COVID-19 Mortality

The univariate Cox regression model suggested that leukocytes >10.6 (HR = 2.53, 95% CI: 1.66–3.87; Pcorrected = 0.0001), neutrophils >8.42 (HR = 2.45, 95% CI: 1.59–3.79; Pcorrected = 0.0003), NLR > 8.69 (HR = 2.46, 95% CI: 1.58–3.82; Pcorrected = 0.0003), SII > 1809.21 (HR = 2.49, 95% CI: 1.52–4; Pcorrected = 0.001), MELD score > 9 (HR = 2.34, 95% CI: 1.56–3.5; Pcorrected = 0.0001), and LGI > 2.41 (HR = 2.17, 95% CI: 1.45–3.25; Pcorrected = 0.0006) were predictors of in-hospital mortality (Table 2). However, multivariate Cox regression revealed that only MELD score > 9 (HR = 1.83, 95% CI: 1.2–2.8; Pcorrected = 0.030) was a prognostic factor for COVID-19 mortality (Table 2).

3.5. Correlation Analysis between MELD Score and Inflammation-Related Parameters in Patients with COVID-19

The correlation between the MELD score and the inflammation-related parameters included in the Cox regression model was analyzed using Spearman’s correlation coefficient. MELD score had a weak positive correlation with leukocytes (r = 0.263 [95% CI: 0.139–0.378]; p < 0.0001), neutrophils (r = 0.270 [95% CI: 0.146–0.384]; p < 0.0001), NLR (r = 0.285 [95% CI: 0.163–0.399]; p < 0.0001), SII (r = 0.240 [95% CI: 0.116–0.357]; p = 0.0002), and LGI (r = 0.266 [95% CI: 0.143–0.381]; p < 0.0001) (Figure 3A–E).

3.6. Leukocyte Glucose Index Can Predict a MELD Score >9 in Patients with COVID-19

Since MELD uses three target variables (bilirubin, creatinine, and INR), we set out to find out whether any of the previously analyzed inflammation-related parameters could predict MELD score values >9 in case any of the variables were missing for the calculation. ROC curves analysis showed that the AUC of LGI for predicting MELD score >9 was 0.68 (95% CI: 0.62–0.74; p < 0.0001; sensitivity = 68.18%; specificity = 63.7%) being higher than for the AUC of leukocytes (0.66), neutrophils (0.66), NLR (0.67), and SII (0.63) (Figure 4A,B).
According to previous results of ROC curves, these inflammation-related parameters were selected to perform univariate regression analysis. The univariate regression showed that the Odds Ratios (OR) of leukocytes > 12.9, neutrophils > 10.26, NLR > 12.894, SII > 3384, and LGI > 1.673 were 3.47, 3.41, 3.34, 2.65, and 3.76 for predicting MELD score >9, respectively (Table 3). Nevertheless, only LGI > 1.673 was a predictor of MELD score >9 (OR = 2.42, 95% CI: 1.21–4.83; Pcorrected = 0.045) for patients with COVID-19 in the multivariate logistic regression analysis (Table 3).

4. Discussion

Although a vaccine against COVID-19 is now available, SARS-CoV-2 outbreaks still occur today [20]. Hence, exploring biomarkers that identify the risk of COVID-19 mortality in different populations is essential. This study evaluated the predictive value of the MELD score for mortality in Mexican patients with COVID-19. The MELD score was significantly higher in the non-survivors than in survivors among Egyptian patients with chronic liver disease and COVID-19 [10]. A study in Turkey demonstrated that a MELD score of 18.5 predicts COVID-19 mortality with an AUC of 0.797, sensitivity = 99%, and specificity = 100% [9]. In contrast, our analysis of the MELD score in the Mexican population revealed that a cut-off point >9 had an AUC of 0.62 with a sensitivity of 53.68% and specificity of 78.42% for predicting COVID-19 mortality. The HR = 1.83 of MELD score for mortality in patients with SARS-CoV-2 infection obtained in our study was similar to the HR = 1.063 reported in a Turkish population [9]. Another study on MELD scores in COVID-19 patients in the United States reported that a MELD score ≥10 was associated with the 39% of mortality [8], while our study indicated that 53.7% of COVID-19 mortality was related to MELD score >9. The mortality rate of patients with COVID-19 in the United States, Turkey, and Mexico ranges from 3.14 to 61.51% [21]. The sensitivity (50%) and specificity (75%) of MELD score ≥10 for predicting SARS-CoV-2 mortality risk in the United States population [8] was very similar to the sensitivity (53.68%) and specificity (73.38%) of MELD score >9 observed in our analysis. Unlike these studies, our analysis included Pcorrected values using Bonferroni corrections to compensate for the effect of multiple hypotheses testing. Interestingly, even when p values were adjusted, the MELD score consistently predicted COVID-19 mortality.
Although Kaplan–Meier survival curves showed that mortality was significantly associated with leukocytes, neutrophils, NLR, SII, MELD, and LGI according to their best cut-off points, the multivariate Cox regression analysis revealed that MELD score >9 was an independent predictor of COVID-19 mortality. Interestingly, we found a weak positive correlation between the values of MELD score and leukocytes, neutrophils, NLR, SII, and LGI in COVID-19 patients. The leukocytes, neutrophils, NLR, SII, and LGI were associated with clinical prognosis in SARS-CoV-2-infected subjects [16,17,22,23,24]. Nevertheless, these biomarkers were not predictors of mortality among the patients with SARS-CoV-2 infection despite a statistically significant AUC when the multivariate Cox regression analysis was performed. Other biomarkers of COVID-19, such as PLR [25], LDH/lymphocyte ratio [18], ALRI [11], ANRI [13], APRI [12], and BUN/creatinine [19], were analyzed in this study. Still, they showed no significant differences (Pcorrected > 0.05) between survivors and non-survivors when the p values were adjusted. Therefore, these variables were excluded from the univariate Cox regression analysis. Some studies suggested that the association between biomarkers and COVID-19 depends heavily on population, study period, and quality of evidence [26,27,28].
The association between LGI and MELD score (OR = 2.42, 95% CI: 1.21–4.83; Pcorrected = 0.045) suggested that, from an inflammatory point of view, LGI > 1.673 roughly corresponds to MELD score > 9 in patients with SARS-CoV-2 infection. Liver is an organ susceptible to SARS-CoV-2 infection [29]. The patients infected with SARS-CoV-2 included in this study had liver abnormalities because their AST and ALT levels were elevated, as previously reported [30]. These values showed no significant difference between surviving and non-surviving subjects. However, the patients had no liver injury because they did not show an increase in ALT or AST levels of at least three times the upper limit of normal, according to the definition suggested by Ding et al. [30]. Therefore, our study indicated that the MELD score could predict COVID-19 mortality even without liver injury in the patients. One hypothesis is that liver abnormalities or hepatic function secondary to inflammation during SARS-CoV-2 infection could be evaluated using the MELD score. This score has been shown to have a significant value in predicting clinical outcomes in the context of patients with human immunodeficiency virus (HIV) [31], hepatitis C virus [32], and hepatitis A virus [33] infections.
The present study has limitations: (1) it was retrospective, (2) single-center, and (3) had a relatively small sample size, possibly leading to biased results. Another limitation is that most of the studies on the biomarker for COVID-19 were conducted in European and Asian countries. Hence, the comparisons made in this study may needed to have been stronger. This study has some strengths, such as the ability of the MELD score to predict COVID-19 mortality compared with other biomarkers. Kaya et al. demonstrated that a high MELD score independently predicts the ICU admission and intubation requirements [9]. Another study could address the predictive value of the MELD score and the other biomarkers for the ICU admission or the need for respiratory support in the Mexican population. For the time being, our study included only patients admitted to the ICU with mechanical ventilation who met the other inclusion criteria.

5. Conclusions

In summary, this study suggested that MELD score >9 at admission can be an essential tool to help identify the mortality risk in patients infected with SARS-CoV-2 to early medical intervention. Incorporation and validation of the MELD score as a biomarker in the Mexican population can help standardize and propose optimal cut-off points worldwide.

Author Contributions

Conceptualization: J.M.R.-R., A.C.A.-S., G.M.-M., J.F.O.-R., L.A.D.J.-G., S.N.P.-R., C.N.F.-M., C.V.L.-L., M.L.-J., V.B.-D. and R.M.D.Á.; data curation: J.M.R.-R., G.M.-M., A.C.A.-S., J.F.O.-R., L.A.D.J.-G. and R.M.D.Á.; formal analysis: J.M.R.-R., G.M.-M., J.F.O.-R., L.A.D.J.-G., S.N.P.-R. and R.M.D.Á.; funding acquisition: J.M.R.-R. and R.M.D.Á.; investigation: J.M.R.-R., A.C.A.-S., G.M.-M., S.N.P.-R., J.F.O.-R., C.N.F.-M., L.A.D.J.-G., C.V.L.-L., M.L.-J., V.B.-D. and R.M.D.Á.; methodology: J.M.R.-R., A.C.A.-S., G.M.-M., L.A.D.J.-G., J.F.O.-R., C.N.F.-M., C.V.L.-L., M.L.-J., V.B.-D. and R.M.D.Á.; project administration: J.M.R.-R. and R.M.D.Á.; resources: J.M.R.-R. and R.M.D.Á.; supervision: J.M.R.-R., G.M.-M. and R.M.D.Á.; validation: J.M.R.-R., G.M.-M., L.A.D.J.-G., S.N.P.-R., J.F.O.-R., C.N.F.-M., C.V.L.-L., M.L.-J., V.B.-D. and R.M.D.Á.; visualization: J.M.R.-R., A.C.A.-S., G.M.-M., S.N.P.-R., J.F.O.-R., C.N.F.-M., C.V.L.-L., M.L.-J., V.B.-D. and L.A.D.J.-G.; writing—original draft preparation: J.M.R.-R., A.C.A.-S., G.M.-M., S.N.P.-R., J.F.O.-R., C.N.F.-M., L.A.D.J.-G., C.V.L.-L., M.L.-J., V.B.-D. and R.M.D.Á.; writing—review and editing: J.M.R.-R., A.C.A.-S., G.M.-M., S.N.P.-R., L.A.D.J.-G., J.F.O.-R., C.N.F.-M., C.V.L.-L., M.L.-J., V.B.-D. and R.M.D.Á. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by FUNDACIÓN IMSS, A.C.

Institutional Review Board Statement

This study was conducted according to the guidelines of the Declaration of Helsinki and was approved in 2024 by the Research Ethical Committee of the UMAE H. E. No. 14 (R-2024-3001-113).

Informed Consent Statement

Given the retrospective nature of this study, the Research Ethical Committee of the UMAE, Hospital de Especialidades No. 14, CMN “Adolfo Ruiz Cortines” from the Mexican Social Security Institute (Registry code: CONBIOÉTICA-30-CEI-003–20,180,412; COFEPRIS 17CI30193067) approved our request to waive the need for informed consent.

Data Availability Statement

Data supporting the reported results can be provided upon reasonable request by the corresponding author.

Acknowledgments

The authors would like to thank all of the health workers, doctors, nurses, and supportive staff working in the UMAE, H. E. No. 14, Centro Médico Nacional “Adolfo Ruiz Cortines”, IMSS Veracruz, who were fighting against COVID-19 together.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Kumar, A.; Singh, R.; Kaur, J.; Pandey, S.; Sharma, V.; Thakur, L.; Sati, S.; Mani, S.; Asthana, S.; Sharma, T.K.; et al. Wuhan to World: The COVID-19 Pandemic. Front. Cell. Infect. Microbiol. 2021, 11, 596201. [Google Scholar] [CrossRef] [PubMed]
  2. Chen, F.; Chen, W.; Chen, J.; Xu, D.; Xie, W.; Wang, X.; Xie, Y. Clinical features and risk factors of COVID-19-associated liver injury and function: A retrospective analysis of 830 cases. Ann. Hepatol. 2021, 21, 100267. [Google Scholar] [CrossRef] [PubMed]
  3. Morgan, K.; Samuel, K.; Vandeputte, M.; Hayes, P.C.; Plevris, J.N. SARS-CoV-2 Infection and the Liver. Pathogens 2020, 9, 430. [Google Scholar] [CrossRef] [PubMed]
  4. Krishnan, A.; Prichett, L.; Tao, X.; Alqahtani, S.A.; Hamilton, J.P.; Mezey, E.; Strauss, A.T.; Kim, A.; Potter, J.J.; Chen, P.-H.; et al. Abnormal liver chemistries as a predictor of COVID-19 severity and clinical outcomes in hospitalized patients. World J. Gastroenterol. 2022, 28, 570–587. [Google Scholar] [CrossRef] [PubMed]
  5. Alva, N.V.; Méndez, O.R.; Gasca, J.C.; Salvador, I.; Hernández, N.; Valdez, M. Liver injury due to COVID-19 in critically ill adult patients. A retrospective study. Rev. Gastroenterol. Mex. (Engl. Ed.) 2024, 89, 57–63. [Google Scholar] [CrossRef]
  6. Licata, A.; Minissale, M.G.; Distefano, M.; Montalto, G. Liver injury, SARS-CoV-2 infection and COVID-19: What physicians should really know? GastroHep 2021, 3, 121–130. [Google Scholar] [CrossRef]
  7. Singal, A.K.; Kamath, P.S. Model for End-stage Liver Disease. J. Clin. Exp. Hepatol. 2013, 3, 50–60. [Google Scholar] [CrossRef]
  8. Stawinski, P.M.; Dziadkowiec, K.N.; Al-Abbasi, B.; Suarez, L.; Simms, L.; Dewaswala, N.; Torres, P.; Al Rubaye, A.; Pino, J.; Marcus, A. Model of End-Stage Liver Disease (MELD) Score as a Predictor of In-Hospital Mortality in Patients with COVID-19: A Novel Approach to a Classic Scoring System. Cureus 2021, 13, e15179. [Google Scholar] [CrossRef]
  9. Kaya, Y.; Gülcü, O.; Aksakal, E.; Kalkan, K.; Aydın, Ş.; Kaya, A.; Bostan, S. A significant predictor of in-hospital and long-term mortality and progression in COVID-19 patients: The end-stage liver disease (MELD) score model. J. Med. Virol. 2023, 95, e28109. [Google Scholar] [CrossRef]
  10. Abdel-Samiee, M.; Shaldoum, M.; Abdelsameea, E.; Awad, S.M.; Omar, N.A. Impact of COVID-19 on Liver Functions Tests in Egyptian Patients with or without Chronic Liver Disease. Afro-Egypt J. Infect. Endem Dis. 2024, 14, 75–84. [Google Scholar] [CrossRef]
  11. Reyes-Ruiz, J.M.; García-Hernández, O.; Martínez-Mier, G.; Osuna-Ramos, J.F.; De Jesús-González, L.A.; Farfan-Morales, C.N.; Palacios-Rápalo, S.N.; Cordero-Rivera, C.D.; Ordoñez-Rodríguez, T.; Ángel, R.M.d. The Role of Aspartate Aminotransferase-to-Lymphocyte Ratio Index (ALRI) in Predicting Mortality in SARS-CoV-2 Infection. Microorganisms 2023, 11, 2894. [Google Scholar] [CrossRef]
  12. Gemcioglu, E.; Davutoglu, M.; Catalbas, R.; Karabuga, B.; Kaptan, E.; Aypak, A.; Kalem, A.K.; Özdemir, M.; Yeşilova, N.Y.; A Kalkan, E.; et al. Predictive values of biochemical markers as early indicators for severe COVID-19 cases in admission. Future Virol. 2021, 16, 353–367. [Google Scholar] [CrossRef]
  13. Huang, D.; Yang, H.; Yu, H.; Wang, T.; Chen, Z.; Yao, R.; Liang, Z. Diagnostic Value of Hematological and Biochemical Parameters Combinations for Predicting Coronavirus Disease 2019 (COVID-19) in Suspected Patients. Am. J. Med. Sci. 2021, 362, 387–395. [Google Scholar] [CrossRef] [PubMed]
  14. Xu, J.B.; Xu, C.; Zhang, R.B.; Wu, M.; Pan, C.K.; Li, X.J.; Wang, Q.; Zeng, F.; Zhu, S. Associations of procalcitonin, C-reaction protein and neutrophil-to-lymphocyte ratio with mortality in hospitalized COVID-19 patients in China. Sci. Rep. 2020, 10, 15058. [Google Scholar] [CrossRef]
  15. Yang, A.P.; Liu, J.P.; Tao, W.Q.; Li, H.M. The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients. Int. Immunopharmacol. 2020, 84, 106504. [Google Scholar] [CrossRef]
  16. Fois, A.G.; Paliogiannis, P.; Scano, V.; Cau, S.; Babudieri, S.; Perra, R.; Ruzzittu, G.; Zinellu, E.; Pirina, P.; Carru, C.; et al. The Systemic Inflammation Index on Admission Predicts In-Hospital Mortality in COVID-19 Patients. Molecules 2020, 25, 5725. [Google Scholar] [CrossRef] [PubMed]
  17. Ramos-Hernández, W.M.; Soto, L.F.; Del Rosario-Trinidad, M.; Farfan-Morales, C.N.; De Jesús-González, L.A.; Martínez-Mier, G.; Osuna-Ramos, J.F.; Bastida-González, F.; Bernal-Dolores, V.; del Ángel, R.M.; et al. Leukocyte glucose index as a novel biomarker for COVID-19 severity. Sci. Rep. 2022, 12, 14956. [Google Scholar] [CrossRef]
  18. Serin, I.; Sari, N.D.; Dogu, M.H.; Acikel, S.D.; Babur, G.; Ulusoy, A.; Onar, M.I.; Gokce, E.C.; Altunok, O.; Mert, F.Y.; et al. A new parameter in COVID-19 pandemic: Initial lactate dehydrogenase (LDH)/Lymphocyte ratio for diagnosis and mortality. J. Infect. Public Health 2020, 13, 1664–1670. [Google Scholar] [CrossRef]
  19. Ok, F.; Erdogan, O.; Durmus, E.; Carkci, S.; Canik, A. Predictive values of blood urea nitrogen/creatinine ratio and other routine blood parameters on disease severity and survival of COVID-19 patients. J. Med. Virol. 2021, 93, 786–793. [Google Scholar] [CrossRef]
  20. Hussein, H.A.M.; Thabet, A.A.; Wardany, A.A.; El-Adly, A.M.; Ali, M.; Hassan, M.E.A.; Abdeldayem, M.A.B.; Mohamed, A.-R.M.A.; Sobhy, A.; El-Mokhtar, M.A.; et al. SARS-CoV-2 outbreak: Role of viral proteins and genomic diversity in virus infection and COVID-19 progression. Virol. J. 2024, 21, 75. [Google Scholar] [CrossRef]
  21. Dessie, Z.G.; Zewotir, T. Mortality-related risk factors of COVID-19: A systematic review and meta-analysis of 42 studies and 423,117 patients. BMC Infect. Dis. 2021, 21, 855. [Google Scholar] [CrossRef] [PubMed]
  22. Zhao, X.; Wang, K.; Zuo, P.; Liu, Y.; Zhang, M.; Xie, S.; Zhang, H.; Chen, X.; Liu, C. Early decrease in blood platelet count is associated with poor prognosis in COVID-19 patients—Indications for predictive, preventive, and personalized medical approach. EPMA J. 2020, 11, 139–145. [Google Scholar] [CrossRef] [PubMed]
  23. Citu, C.; Gorun, F.; Motoc, A.; Sas, I.; Gorun, O.M.; Burlea, B.; Tuta-Sas, I.; Tomescu, L.; Neamtu, R.; Malita, D.; et al. The Predictive Role of NLR, d-NLR, MLR, and SIRI in COVID-19 Mortality. Diagnostics 2022, 12, 122. [Google Scholar] [CrossRef] [PubMed]
  24. Ghobadi, H.; Mohammadshahi, J.; Javaheri, N.; Fouladi, N.; Mirzazadeh, Y.; Aslani, M.R. Role of leukocytes and systemic inflammation indexes (NLR, PLR, MLP, dNLR, NLPR, AISI, SIR-I, and SII) on admission predicts in-hospital mortality in non-elderly and elderly COVID-19 patients. Front. Med. 2022, 9, 916453. [Google Scholar] [CrossRef] [PubMed]
  25. Simon, P.; Le Borgne, P.; Lefevbre, F.; Cipolat, L.; Remillon, A.; Dib, C.; Hoffmann, M.; Gardeur, I.; Sabah, J.; Kepka, S.; et al. Platelet-to-Lymphocyte Ratio (PLR) Is Not a Predicting Marker of Severity but of Mortality in COVID-19 Patients Admitted to the Emergency Department: A Retrospective Multicenter Study. J. Clin. Med. 2022, 11, 4903. [Google Scholar] [CrossRef]
  26. Eslamijouybari, M.; Heydari, K.; Maleki, I.; Moosazadeh, M.; Hedayatizadeh-Omran, A.; Vahedi, L.; Ghasemian, R.; Sharifpour, A.; Alizadeh-Navaei, R. Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios in COVID-19 Patients and Control Group and Relationship with Disease Prognosis. Casp. J. Intern. Med. 2020, 11 (Suppl. S1), 531–535. [Google Scholar]
  27. Mousavi, S.A.; Rad, S.; Rostami, T.; Rostami, M.; Mousavi, S.A.; Mirhoseini, S.A.; Kiumarsi, A. Hematologic predictors of mortality in hospitalized patients with COVID-19: A comparative study. Hematology 2020, 25, 383–388. [Google Scholar] [CrossRef]
  28. Sarkar, S.; Kannan, S.; Khanna, P.; Singh, A.K. Role of platelet-to-lymphocyte count ratio (PLR), as a prognostic indicator in COVID-19: A systematic review and meta-analysis. J. Med. Virol. 2022, 94, 211–221. [Google Scholar] [CrossRef]
  29. Wanner, N.; Andrieux, G.; Badia-i-Mompel, P.; Edler, C.; Pfefferle, S.; Lindenmeyer, M.T.; Schmidt-Lauber, C.; Czogalla, J.; Wong, M.N.; Okabayashi, Y.; et al. Molecular consequences of SARS-CoV-2 liver tropism. Nat. Metab. 2022, 4, 310–319. [Google Scholar] [CrossRef]
  30. Ding, Z.Y.; Li, G.X.; Chen, L.; Shu, C.; Song, J.; Wang, W.; Wang, Y.; Chen, Q.; Jin, G.; Liu, T.; et al. Association of liver abnormalities with in-hospital mortality in patients with COVID-19. J. Hepatol. 2021, 74, 1295–1302. [Google Scholar] [CrossRef]
  31. Subramanian, A.; Sulkowski, M.; Barin, B.; Stablein, D.; Curry, M.; Nissen, N.; Dove, L.; Roland, M.; Florman, S.; Blumberg, E.; et al. MELD score is an important predictor of pretransplantation mortality in HIV-infected liver transplant candidates. Gastroenterology 2010, 138, 159–164. [Google Scholar] [CrossRef] [PubMed]
  32. Butt, A.A.; Ren, Y.; Lo Re, V.I.I.I.; Taddei, T.H.; Kaplan, D.E. Comparing Child-Pugh, MELD, and FIB-4 to Predict Clinical Outcomes in Hepatitis C Virus-Infected Persons: Results From ERCHIVES. Clin. Infect. Dis. 2017, 65, 64–72. [Google Scholar] [CrossRef] [PubMed]
  33. Taylor, R.M.; Davern, T.; Munoz, S.; Han, S.-H.; McGuire, B.; Larson, A.M.; Hynan, L.; Lee, W.M.; Fontana, R.J.; U.S. Acute Liver Failure Study Group. Fulminant hepatitis A virus infection in the United States: Incidence, prognosis, and outcomes. Hepatology 2006, 44, 1589–1597. [Google Scholar] [CrossRef]
Jcm 13 05777 g001
Figure 1. (A,B) Receiver operating characteristic (ROC) curves and accuracy evaluation of leukocytes, neutrophils, NLR, SII, MELD, and LGI in predicting COVID-19 mortality. Abbreviations: NLR, neutrophil-to-lymphocyte ratio; SII, systemic immune-inflammation index; MELD, Model of End-Stage Liver Disease Score; LGI, leukocyte glucose index.
Figure 1. (A,B) Receiver operating characteristic (ROC) curves and accuracy evaluation of leukocytes, neutrophils, NLR, SII, MELD, and LGI in predicting COVID-19 mortality. Abbreviations: NLR, neutrophil-to-lymphocyte ratio; SII, systemic immune-inflammation index; MELD, Model of End-Stage Liver Disease Score; LGI, leukocyte glucose index.
Jcm 13 05777 g001
Jcm 13 05777 g002
Figure 2. Kaplan–Meir survival curves of hospitalized COVID-19 patients according to established best cut-off values of (A) leukocytes, (B) neutrophils, (C) NLR, (D) SII, (E) MELD, and (F) LGI. Overall survival curves were estimated by Kaplan–Meier method and p values, by log-rank test. A p value < 0.05 was considered statistically significant. Abbreviations: NLR, neutrophil-to-lymphocyte ratio; SII, systemic immune-inflammation index; MELD, Model of End-Stage Liver Disease Score; LGI, leukocyte glucose index.
Figure 2. Kaplan–Meir survival curves of hospitalized COVID-19 patients according to established best cut-off values of (A) leukocytes, (B) neutrophils, (C) NLR, (D) SII, (E) MELD, and (F) LGI. Overall survival curves were estimated by Kaplan–Meier method and p values, by log-rank test. A p value < 0.05 was considered statistically significant. Abbreviations: NLR, neutrophil-to-lymphocyte ratio; SII, systemic immune-inflammation index; MELD, Model of End-Stage Liver Disease Score; LGI, leukocyte glucose index.
Jcm 13 05777 g002
Jcm 13 05777 g003
Figure 3. Spearman correlations between values of the MELD score and the inflammation-related parameters in patients with COVID-19. Scatter plots showing the correlation between MELD and (A) leukocytes, (B) neutrophils, (C) NLR, (D) SII, and (E) LGI. Spearman’s test was used to evaluate the correlations. A p value < 0.05 was considered statistically significant. Abbreviations: NLR, neutrophil-to-lymphocyte ratio; SII, systemic immune-inflammation index; MELD, Model of End-Stage Liver Disease Score; LGI, leukocyte glucose index.
Figure 3. Spearman correlations between values of the MELD score and the inflammation-related parameters in patients with COVID-19. Scatter plots showing the correlation between MELD and (A) leukocytes, (B) neutrophils, (C) NLR, (D) SII, and (E) LGI. Spearman’s test was used to evaluate the correlations. A p value < 0.05 was considered statistically significant. Abbreviations: NLR, neutrophil-to-lymphocyte ratio; SII, systemic immune-inflammation index; MELD, Model of End-Stage Liver Disease Score; LGI, leukocyte glucose index.
Jcm 13 05777 g003
Jcm 13 05777 g004
Figure 4. (A,B) Receiver operating characteristic (ROC) curves and accuracy evaluation of leukocytes, neutrophils, NLR, SII, and LGI in the predicting MELD score >9. Abbreviations: NLR, neutrophil-to-lymphocyte ratio; SII, systemic immune-inflammation index; MELD, Model of End-Stage Liver Disease Score; LGI, leukocyte glucose index.
Figure 4. (A,B) Receiver operating characteristic (ROC) curves and accuracy evaluation of leukocytes, neutrophils, NLR, SII, and LGI in the predicting MELD score >9. Abbreviations: NLR, neutrophil-to-lymphocyte ratio; SII, systemic immune-inflammation index; MELD, Model of End-Stage Liver Disease Score; LGI, leukocyte glucose index.
Jcm 13 05777 g004
Table 1. Baseline characteristics.
Table 1. Baseline characteristics.
VariableOverall (n = 234)Survival Group (n = 139)Non-Survival Group (n = 95)p-ValueAdjusted p-Value
Sex, female71 (30.34%)41 (29.49%)30 (31.57%)0.7341
Age (years old)63.27 ± 12.9162.74 ± 12.67865.23 ± 13.860.0050.190
Height (m)1.6 ± 0.91.6 ± 0.091.59 ± 0.10.9101
Weight (kg)73.25 (22.5)74 (20.75)67 (21.25)0.2201
BMI (kg/m2)28.07 (6.1)28.34 (5.57)27.4 (7)0.3391
Diabetes114 (48.71%)79 (56.83%)35 (36.84%)0.0030.114
Hypertension112 (47.86%)70 (50.35%)42 (44.21%)0.3551
FiO2 (%)50 (39)41 (31)60 (47)0.0080.304
SpO2 (%)64 (39)71 (38)58.5 (35)0.0421
Hemoglobin (g/dL)14.5 (2.7)14.5 (2.4)14.5 (3.2)0.3731
Hematocrit (%)44 (8)44 (7)44 (7)0.3771
MCV91 (6)91 (6)91 (5)0.1521
MCH30.2 (2.3)30.2 (2.3)30.2 (2.2)0.6211
Leukocytes (×109/L)10.45 (7)9.5 (6.7)12.6 (7.3)0.00010.003
Neutrophils (×109/L)8.74 (6.8)7.72 (6.32)11.39 (7.52)0.00010.003
Lymphocytes (×109/L)0.81 (0.7)0.86 (0.72)0.76 (0.65)0.1221
Platelets (×109/L)252 (135)246 (130)267 (128)0.3551
INR1.05 (0.17)1.03 (0.16)1.08 (0.18)0.0481
Glucose (mg/dL)143 (120)132.5 (105)158 (142)0.0060.228
Urea (mg/dL)45.8 (45.8)38.2 (38.6)57.1 (58.6)0.0080.304
Creatinine (mg/dL)0.9 (0.7)0.9 (0.5)1.1 (1.1)0.0040.152
LDH (U/L)850 (472)820 (462)916 (465)0.0080.304
BUN21.4 (20.8)17.75 (17.82)27 (27.5)0.0020.076
TB (mg/dL)0.6 (0.4)0.5 (0.4)0.6 (0.37)0.2751
DB (mg/dL)0.3 (0.2)0.2 (0.2)0.3 (0.2)0.0040.152
IB (mg/dL)0.3 (0.2)0.3 (0.15)0.3 (0.2)0.1861
AST (IU/L)46 (44)42.5 (47)49 (40)0.3311
ALT (IU/L)37 (38)41.5 (45)32 (30)0.1751
ALRI60 (75.13)53.31 (69.67)65.04 (74.87)0.2411
APRI0.48 (0.61)0.49 (0.63)0.46 (0.52)0.7851
ANRI4.59 (7.07)5.14 (8.18)4.41 (5.85)0.1781
NLR9.44 (12.15)8.06 (11.02)14.57 (15.19)0.00010.003
PLR284.67 (267.33)265.83 (238.26)329.78 (302.1)0.0581
SII2525.03 (3503.23)2149.52 (2759.38)3017.84 (3976.29)0.0010.038
MELD8 (5)8 (3)10 (7)0.0010.038
LGI1.61 (1.61)1.36 (1.4)1.88 (2)0.00010.003
LDH/LR1038.27 (1091.26)933.76 (955.81)1193.15 (1237.85)0.0140.504
BUN/Cr20.4 (12.79)20.69 (13.19)20 (14.63)0.4381
Data are mean ± standard deviation, median (interquartile range), n (%). p values were calculated by Student´s-t test, Mann–Whitney U test or Chi-squared test as appropriate. The bold values provide statistically significance (p < 0.05). Abbreviations: BMI, body mass index; FiO2, fraction of inspired oxygen; SpO2, oxygen saturation; MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin; INR, international normalized ratio; LDH, lactate dehydrogenase; BUN, blood urea nitrogen; TB, total bilirubin; DB, direct bilirubin; IB, indirect bilirubin; AST, Aspartate aminotransferase; ALT, Alanine aminotransferase ALRI, aspartate aminotransferase-to-lymphocyte ratio index; APRI, aspartate aminotransferase-to-platelet ratio index; ANRI, aspartate aminotransferase-to-neutrophil ratio index; NLR, neutrophil-to-lymphocyte ratio; PLR, platelets-to-lymphocyte ratio; SII, systemic immune-inflammation index; MELD, Model of End-Stage Liver Disease Score; LGI, leukocyte glucose index; LDH/LR, lactate dehydrogenase/lymphocyte ratio; BUN/Cr, BUN-to-creatinine ratio.
Table 2. Univariate and multivariate Cox regression analysis for predicting of COVID-19 mortality.
Table 2. Univariate and multivariate Cox regression analysis for predicting of COVID-19 mortality.
Univariate Multivariate
VariableHR95% CIp-ValueAdjusted p-ValueHR95% CIp-ValueAdjusted p-Value
Leukocytes2.531.66–3.87<0.00010.00011.550.62–3.860.3421
Neutrophils2.451.59–3.79<0.00010.00030.960.36–2.510.9391
NLR2.461.58–3.82<0.00010.00031.340.73–2.450.3401
SII2.491.52–40.00020.0011.460.75–2.830.2551
MELD2.341.56–3.5<0.00010.00011.831.2–2.80.0050.030
LGI2.171.45–3.250.00010.00061.20.74.1.950.4441
Univariate Cox regression analysis was performed with the six variables that had statistically significant difference in the Table 1 using the multiple hypotheses (Pcorrected < 0.05). Candidate predictors with statistically significant difference (Pcorrected < 0.05) in univariate Cox regression analysis were included in multivariate Cox regression analysis. Hazard ratio (HR) and 95% Confidence Interval (CI 95%) were reported. The bold values provide statistically significance (Pcorrected < 0.05). Abbreviations: NLR, neutrophil-to-lymphocyte ratio; SII, systemic immune-inflammation index; MELD, Model of End-Stage Liver Disease Score; LGI, leukocyte glucose index.
Table 3. Univariate and multivariate logistic regression analysis for predicting MELD score >9 in patients with COVID-19.
Table 3. Univariate and multivariate logistic regression analysis for predicting MELD score >9 in patients with COVID-19.
Univariate Multivariate
VariableOR95% CIp-ValueAdjusted p-ValueOR95% CIp-ValueAdjusted p-Value
Leukocytes3.471.97–6.11<0.00010.00051.640.49–5.460.4151
Neutrophils3.411.96–5.94<0.00010.00050.890.25–3.110.8641
NLR3.341.92–5.82<0.00010.00052.251.1–5.130.0520.260
SII2.651.52–4.60.0010.0050.980.43–2.210.9651
LGI3.762.14–6.59<0.00010.00022.421.21–4.830.0090.045
Univariate logistic regression analysis was performed with the five previously analyzed inflammation-related parameters that had statistically significant difference using the multiple hypotheses (Pcorrected < 0.05). Candidate predictors with statistically significant difference (Pcorrected < 0.05) in univariate Logistic regression analysis were included in multivariate logistic regression analysis. The Odds Ratio (OR) and 95% Confidence Interval (CI 95%) were reported. The bold values provide statistically significancy (Pcorrected < 0.05). Abbreviations: NLR, neutrophil-to-lymphocyte ratio; SII, systemic immune-inflammation index; MELD, Model of End-Stage Liver Disease Score; LGI, leukocyte glucose index.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Reyes-Ruiz, J.M.; Avelino-Santiago, A.C.; Martínez-Mier, G.; López-López, C.V.; De Jesús-González, L.A.; León-Juárez, M.; Osuna-Ramos, J.F.; Farfan-Morales, C.N.; Palacios-Rápalo, S.N.; Bernal-Dolores, V.; et al. The Model for End-Stage Liver Disease (MELD) Score Predicting Mortality Due to SARS-CoV-2 in Mexican Patients. J. Clin. Med. 2024, 13, 5777. https://doi.org/10.3390/jcm13195777

AMA Style

Reyes-Ruiz JM, Avelino-Santiago AC, Martínez-Mier G, López-López CV, De Jesús-González LA, León-Juárez M, Osuna-Ramos JF, Farfan-Morales CN, Palacios-Rápalo SN, Bernal-Dolores V, et al. The Model for End-Stage Liver Disease (MELD) Score Predicting Mortality Due to SARS-CoV-2 in Mexican Patients. Journal of Clinical Medicine. 2024; 13(19):5777. https://doi.org/10.3390/jcm13195777

Chicago/Turabian Style

Reyes-Ruiz, José Manuel, Ana Citlali Avelino-Santiago, Gustavo Martínez-Mier, Claudia Vanessa López-López, Luis Adrián De Jesús-González, Moises León-Juárez, Juan Fidel Osuna-Ramos, Carlos Noe Farfan-Morales, Selvin Noé Palacios-Rápalo, Víctor Bernal-Dolores, and et al. 2024. "The Model for End-Stage Liver Disease (MELD) Score Predicting Mortality Due to SARS-CoV-2 in Mexican Patients" Journal of Clinical Medicine 13, no. 19: 5777. https://doi.org/10.3390/jcm13195777

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop